题名：Manipulation of the infectious bronchitis coronavirus genome for vaccine development and analysis of the accessory proteins
作者：Dave Cavanagh, Rosa Casais, Maria Armesto, Teri Hodgson, Sousan Izadkhasti, Marc Davies, Fengsheng Lin, Ian Tarpey and Paul Britton
来源：Vaccine[IF=2.822], In Press, Corrected Proof, Available online 6 March 2007,
摘要： Dave Cavanagha, , , Rosa Casaisa, Maria Armestoa, Teri Hodgsona, Sousan Izadkhastia, Marc Daviesa, Fengsheng Linb, Ian Tarpeyb and Paul Brittona
aInstitute for Animal Health, Compton Laboratory, Newbury, Berkshire RG20 7NN, UK
bIntervet UK, Walton Manor, Walton, Milton Keynes, Buckinghamshire MK7 7AJ, UK
Received 23 June 2006; revised 12 January 2007; accepted 16 February 2007. Available online 6 March 2007.
Infectious bronchitis coronavirus (IBV) is the cause of the single most economically costly infectious disease of domestic fowl in the UKand probably so in many countries that have a developed poultry industry. A major reason for its continued dominance is its existence as many serotypes, determined by the surface spike protein (S), cross-protection being poor. Although controlled to some degree by live and inactivated vaccines, a new generation of IB vaccines is called for. Reverse genetic or infectious clone systems, which allow the manipulation of the IBV genome, are key to this development. New vaccines would ideally be: genetically stable (i.e. maintain a stable attenuated phenotype); administered in ovo; and be flexible with respect to the source of the spike protein gene. Rational attenuation of IBV requires the identification of genes that are simultaneously not essential for replication and whose absence would reduce pathogenicity. Being able to modify a core vaccine strain to make it applicable to a prevailing serotype requires a procedure for doing so, and the demonstration that spike-swapping is sufficient to induce good immunity.
We have demonstrated that four small IBV proteins, encoded by genes 3 and 5, are not essential for replication; failure to produce these proteins had little detrimental affect on the titre of virus produced. Our current molecularly cloned IBV, strain Beaudette, is non-pathogenic, so we do not know what effect the absence of these proteins would have on pathogenicity. That said, plaque size and composition of various gene 3/5 recombinant IBVs in cell culture, and reduced output and ciliostasis in tracheal organ cultures, shows that they are less aggressive than the wild-type Beaudette. Consequently these genes remain targets for rational attenuation. We have recently obtained evidence that one or more of the 15 proteins encoded by gene 1 are also determinants of pathogenicity. Hence gene 1 is also a target for rational attenuation.
Replacing the S protein gene of Beaudette with that from the pathogenic M41 strain resulted in a recombinant virus that was still non-pathogenic but which did induce protection against challenge with M41. We have since made other spike-swapped recombinants, including ones with chimaera S genes. Uniquely, our molecular clone of Beaudette is benign when administered to 18-day-old embryos, even at high doses, and induces immunity after this route of vaccination.
Taken together, our results point to the creation of a new generation of IB vaccines, based on rational modification of the genome, as being a realisable objective.